# Thermo Fisher Q3 2026 Earnings Beat

> Thermo Fisher reports 9% revenue growth and 15% adjusted EPS surge as AI and end markets drive expansion.
- Title: Thermo Fisher Q3 2026 Earnings Beat · The Motley Fool
- Summary: Thermo Fisher reports 9% revenue growth and 15% adjusted EPS surge as AI and end markets drive expansion. Thermo Fisher's Q3 2026 results exceeded guidance…
- Keywords: thermo fisher, q3 2026, revenue growth, adjusted eps, ai integration, pharma, biotech, end markets, capital deployment, free cash flow, finance, money
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/10/21/thermo-fisher-tmo-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-10-21T16:57:53+00:00
- Read time: 2 min
- Topics: thermo fisher, q3 2026, revenue growth, adjusted eps, ai integration, pharma, biotech, end markets, capital deployment, free cash flow, finance, money
## Q3 Results
Thermo Fisher reported $12.14 billion revenue, 9% year-over-year growth, and $6.68 adjusted EPS, 15% higher than prior year.
## Organic Growth
Organic revenue grew 6% driven by strong pharma, biotech, and industrial end markets with flat academic and government performance.
## Adjusted EPS
Adjusted EPS rose 15% to $6.68, reflecting strong operational execution and improved end-market conditions.
## Tariff Refund Impact
Net tariff refund recovery of $60 million boosted adjusted operating income and $0.15 on adjusted EPS.
## R&D Investment
R&D spending reached $350 million, 6.7% of manufacturing revenue, focused on high-impact innovation.
## Microbiology Divestiture
Completed sale of microbiology business generated $1 billion in proceeds and reduced revenue by 1%.
## AI Integration
AI-enabled software automates workflows in electron microscopy, reducing manual setup time by 90%.
## Orbitrap Isora Launch
Orbitrap Isora mass spectrometer launched for isotope ratio analysis in environmental and life sciences research.
## Ion 560 Chip
Ion 560 Chip launched for Ion GeneStudio S5 platform, providing nearly twice the sequencing capacity.
## Precure Initiative
Precure initiative with Mayo Clinic uses proteomics and Orbitrap mass spectrometry for patient sample analysis.
## AI-Automation Center
First AI-Automation Innovation Center opened in South Korea for customer collaboration on scientific workflows.
## Full-Year Guidance
Full-year revenue guidance raised to $47.7 billion-$48.2 billion with 7%-8% growth over 2025.
## Capital Deployment
Completed $1 billion microbiology divestiture and $4 billion share repurchases for 2026.
## PPI Business System
PPI Business System enabled 120 basis points of adjusted operating margin expansion and strong earnings growth.
## End Market Performance
Pharma and biotech grew high single digits, industrial and applied grew high single digits, diagnostics grew low single digits.
## 2026 Outlook
Thermo Fisher expects 10%-11% adjusted EPS growth and 4% organic revenue growth for full year 2026.
## Key takeaway

Thermo Fisher's Q3 2026 results exceeded guidance with $12.14 billion revenue, 6% organic growth, and $6.68 adjusted EPS, fueled by strong pharma and biotech performance and AI integration.